University of Pittsburgh

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Pittsburgh sits in the top decile of US sponsors by registered trial count (#22 of 15,742 sponsors by registered trial count).

1,238 total trials 160 currently recruiting 917 completed early-phase tilt top decile by trial count

University of Pittsburgh: 1,238 sponsored US clinical trials, 160 recruiting.

University of Pittsburgh sponsors 1,238 registered US clinical trials on ClinicalTrials.gov, 160 of them currently recruiting, and 917 completed. 84 of these trials are in Phase 3-4 (later-stage) and 160 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of Pittsburgh ranks in the top decile of sponsors by registered trial count (#22 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 66/100

917 of 1,014 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,238 total, page 20 of 25

COMPLETED

Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infectionsin Adults

NCT00524108

COMPLETED

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

NCT00518661

COMPLETED

Fusariosis in Solid-Organ Transplant Recipients

NCT00518778

COMPLETED

The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors

NCT01317147

COMPLETED

Pneumocystis in Pathogenesis of HIV-associated Emphysema

NCT00869544

COMPLETED

Clinical Outcomes and Global Epidemiology -Data Coordinating Center

NCT00524563

COMPLETED

Multi-Tracer Pet Quantitation of Insulin Action

NCT00715221

COMPLETED NA

PET Imaging Study of Recovered Anorexics

NCT00603018

COMPLETED

Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c

NCT00422851

COMPLETED

Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3a Part ii

NCT00494364

COMPLETED NA

Evaluation of Group Lifestyle Balance DVD in Primary Care Practice

NCT00480779

COMPLETED Phase 1

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

NCT00388427

COMPLETED

Chronic Knee Pain Study

NCT00776932

COMPLETED

Etiology of Community Acquired Pneumonia

NCT00471757

COMPLETED Phase 4

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

NCT00696293

COMPLETED

Ventricular Shunt and Drain Infections - Timing of Reimplantation

NCT00470132

COMPLETED NA

Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery

NCT00476021

COMPLETED

Parental Involvement and Children's Extra-Familial Contexts

NCT00538252

COMPLETED NA

Effect of Patient-Centered Care (PCC) on Patient Satisfaction at Hospital Discharge

NCT00499161

COMPLETED

Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures

NCT00475891

COMPLETED Phase 1

Effect of Antacids on Gleevec® in Healthy Volunteers

NCT00446316

COMPLETED

Risk Factors for Carbapenem-resistant Acinetobacter Baumannii

NCT00462579

COMPLETED Phase 1

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

NCT00446004

COMPLETED Phase 1

Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

NCT00445913

COMPLETED Phase 4

'Levonorgestrel IUD Insertion After D&E Procedure

NCT00475228

COMPLETED NA

Exercise Training Study for Patients With Cystic Fibrosis

NCT00609050

COMPLETED

Quinolone Resistance in Bloodstream Isolates of Escherichia Coli

NCT00449735

COMPLETED Phase 2

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

NCT00436787

COMPLETED

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362

COMPLETED

Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC

NCT00443885

COMPLETED

Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase

NCT00414193

COMPLETED

Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes

NCT00446355

COMPLETED NA

Prevention of Depression in Spouses of People With Cognitive Impairment

NCT00321971

COMPLETED

Bone Metabolism and Parathyroid Hormone-related Protein (PTHrP) Lactation Study

NCT00430417

COMPLETED NA

Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients

NCT00447408

COMPLETED NA

Low Sodium Diet and Behavioral Intervention for Reversing Arterial Stiffening in Overweight Individuals

NCT00366990

COMPLETED Phase 2

Psychotherapy for Bipolar II Depression, Pilot Study, Phase II

NCT00411463

COMPLETED Phase 2

Study of PEG-Intron for Plexiform Neurofibromas

NCT00396019

TERMINATED Phase 1

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

NCT00177853

TERMINATED

An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study

NCT00371605

COMPLETED NA

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

NCT00336817

COMPLETED NA

Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal

NCT00409786

COMPLETED NA

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

NCT00336895

COMPLETED Phase 4

Acute Otitis Media (AOM) Therapy Trial in Young Children

NCT00377260

COMPLETED NA

Behavioral Therapy for Reduction in Smoking Craving

NCT00449293

COMPLETED NA

Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

NCT00393874

COMPLETED

Determining Women's Preferences for Medical Abortion Using Willingness to Pay

NCT00472394

COMPLETED

Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)

NCT00896142

COMPLETED NA

Media Literacy to Prevent Adolescent Smoking

NCT00398190

COMPLETED Phase 1

Abuse-Focused Cognitive Behavioral Therapy for Children Who Have Been Physically Abused

NCT00494286

← Previous Page 20 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 81
Phase 2 79
Phase 3 28
Phase 4 56

What is open in the University of Pittsburgh pipeline

160 recruiting of 1,238 indexed (13% open); 917 completed (74%).

Phase mix: 84 late (III/IV) vs 160 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Pittsburgh: open-pipeline peers nationwide

Peers matched on 1,238 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Pittsburgh sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20%22% Total trials Recruiting share University of PittsburghNorthwestern UniversityEmory UniversityUniversity of Colorado, DenverAstraZenecaIntermountain Health CareMcMaster UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Temple University
University of Pittsburgh sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Pittsburgh sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,238 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

What to do with this University of Pittsburgh page

1,238 registered trials is a research-attention snapshot, not an endorsement of University of Pittsburgh or any single study.

  • 160 of University of Pittsburgh's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of Pittsburgh studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Pittsburgh pipeline card: 1,238 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.